Implantable sensors and implantable pumps and anti-scarring agents

• US 20050181010A1
• Filed: 12/01/2004
• Published: 08/18/2005
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Toleikis, Philip M., Gravett, David M., Maiti, Arpita
• Application Number:
  US11/001,789
• Publication Number:
  US 20050181010A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/372 Arrangements in connection with the implantation of stimulators
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

Claims

1-296. -296. (canceled)

297. A device, comprising a blood or tissue glucose monitor (i.e., a sensor) and an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the agent inhibits scarring between the device and a host into which the device is implanted.

298. The device of claim 297 wherein the agent inhibits cell regeneration.

299. The device of claim 297 wherein the agent inhibits angiogenesis.

300. The device of claim 297 wherein the agent inhibits fibroblast migration.

301. The device of claim 297 wherein the agent inhibits fibroblast proliferation.

302. The device of claim 297 wherein the agent inhibits deposition of extracellular matrix.

303. The device of claim 297 wherein the agent inhibits tissue remodeling.

306. The device of claim 297 wherein the agent is a chemokine receptor antagonist.

307. The device of claim 297 wherein the agent is a cell cycle inhibitor.

308. The device of claim 297 wherein the agent is a taxane.

309. The device of claim 297 wherein the agent is an anti-microtubule agent.

310. The device of claim 297 wherein the agent is paclitaxel.

311. The device of claim 297 wherein the agent is not paclitaxel.

312. The device of claim 297 wherein the agent is an analogue or derivative of paclitaxel.

313. The device of claim 297 wherein the agent is a vinca alkaloid.

314. The device of claim 297 wherein the agent is camptothecin or an analogue or derivative thereof.

315. The device of claim 297 wherein the agent is a podophyllotoxin.

316. The device of claim 297 wherein the agent is a podophyllotoxin, wherein the podophyllotoxin is etoposide or an analogue or derivative thereof.

317. The device of claim 297 wherein the agent is an anthracycline.

318. The device of claim 297 wherein the agent is an anthracycline, wherein the anthracycline is doxorubicin or an analogue or derivative thereof.

319. The device of claim 297 wherein the agent is an anthracycline, wherein the anthracycline is mitoxantrone or an analogue or derivative thereof.

320. The device of claim 297 wherein the agent is a platinum compound.

321. The device of claim 297 wherein the agent is a nitrosourea.

322. The device of claim 297 wherein the agent is a nitroimidazole.

323. The device of claim 297 wherein the agent is a folic acid antagonist.

324. The device of claim 297 wherein the,agent is a cytidine analogue.

325. The device of claim 297 wherein the agent is a pyrimidine analogue.

326. The device of claim 297 wherein the agent is a fluoropyrimidine analogue.

327. The device of claim 297 wherein the agent is a purine analogue.

328. The device of claim 297 wherein the agent is a nitrogen mustard or an analogue or derivative thereof.

502. The device of claim 297, further comprising a second pharmaceutically active agent.

504. The device of claim 297, further comprising an agent that inhibits infection.

304-305. -305. (canceled)

329-501. -501. (canceled)

503. (canceled)

505-3900. -3900. (canceled)

3901. A method for inhibiting scarring comprising placing a blood or tissue glucose monitor (i.e., a sensor) and an anti-scarring agent or a composition comprising an anti-scarring agent into an animal host, wherein the agent inhibits scarring.

3902. The method of claim 3901 wherein the agent inhibits cell regeneration.

3903. The method of claim 3901 wherein the agent inhibits angiogenesis.

3904. The method of claim 3901 wherein the agent inhibits fibroblast migration.

3905. The method of claim 3901 wherein the agent inhibits fibroblast proliferation.

3906. The method of claim 3901 wherein the agent inhibits deposition of extracellular matrix.

3907. The method of claim 3901 wherein the agent inhibits tissue remodeling.

3910. The method of claim 3901 wherein the agent is a chemokine receptor antagonist.

3911. The method of claim 3901 wherein the agent is a cell cycle inhibitor.

3912. The method of claim 3901 wherein the agent is a taxane.

3913. The method of claim 3901 wherein the agent is an anti-microtubule agent.

3914. The method of claim 3901 wherein the agent is paclitaxel.

3915. The method of claim 3901 wherein the agent is not paclitaxel.

3916. The method of claim 3901 wherein the agent is an analogue or derivative of paclitaxel.

3917. The method of claim 3901 wherein the agent is a vinca alkaloid.

3918. The method of claim 3901 wherein the agent is camptothecin or an analogue or derivative thereof.

3919. The method of claim 3901 wherein the agent is a podophyllotoxin.

3920. The method of claim 3901 wherein the agent is a podophyllotoxin, wherein the podophyllotoxin is etoposide or an analogue or derivative thereof.

3921. The method of claim 3901 wherein the agent is an anthracycline.

3922. The method of claim 3901 wherein the agent is an anthracycline, wherein the anthracycline is doxorubicin or an analogue or derivative thereof.

3923. The method of claim 3901 wherein the agent is an anthracycline, wherein the anthracycline is mitoxantrone or an analogue or derivative thereof.

3924. The method of claim 3901 wherein the agent is a platinum compound.

3925. The method of claim 3901 wherein the agent is a nitrosourea.

3926. The method of claim 3901 wherein the agent is a nitroimidazole.

3927. The method of claim 3901 wherein the agent is a folic acid antagonist.

3928. The method of claim 3901 wherein the agent is a cytidine analogue.

3929. The method of claim 3901 wherein the agent is a pyrimidine analogue.

3930. The method of claim 3901 wherein the agent is a fluoropyrimidine analogue.

3931. The method of claim 3901 wherein the agent is a purine analogue.

3932. The method of claim 3901 wherein the agent is a nitrogen mustard or an analogue or derivative thereof.

4080. The method of claim 3901, wherein the composition further comprises a second pharmaceutically active agent.

4082. The method of claim 3901, wherein the composition further comprises an agent that inhibits infection.

3908-3909. -3909. (canceled)

3933-4079. -4079. (canceled)

4081. (canceled)

4083-7604. -7604. (canceled)

7605. A method for making a device comprising:

combining a blood or tissue glucose monitor (i.e., a sensor) and an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the agent inhibits scarring between the device and a host into which the device is implanted.

7606. The method of claim 7605 wherein the agent inhibits cell regeneration.

7607. The method of claim 7605 wherein the agent inhibits angiogenesis.

7608. The method of claim 7605 wherein the agent inhibits fibroblast migration.

7609. The method of claim 7605 wherein the agent inhibits fibroblast proliferation.

7610. The method of claim 7605 wherein the agent inhibits deposition of extracellular matrix.

7611. The method of claim 7605 wherein the agent inhibits tissue remodeling.

7614. The method of claim 7605 wherein the agent is a chemokine receptor antagonist.

7615. The method of claim 7605 wherein the agent is a cell cycle inhibitor.

7616. The method of claim 7605 wherein the agent is a taxane.

7617. The method of claim 7605 wherein the agent is an anti-microtubule agent.

7618. The method of claim 7605 wherein the agent is paclitaxel.

7619. The method of claim 7605 wherein the agent is not paclitaxel.

7620. The method of claim 7605 wherein the agent is an analogue or derivative of paclitaxel.

7621. The method of claim 7605 wherein the agent is a vinca alkaloid.

7622. The method of claim 7605 wherein the agent is camptothecin or an analogue or derivative thereof.

7623. The method of claim 7605 wherein the agent is a podophyllotoxin.

7624. The method of claim 7605 wherein the agent is a podophyllotoxin, wherein the podophyllotoxin is etoposide or an analogue or derivative thereof.

7625. The method of claim 7605 wherein the agent is an anthracycline.

7626. The method of claim 7605 wherein the agent is an anthracycline, wherein the anthracycline is doxorubicin or an analogue or derivative thereof.

7627. The method of claim 7605 wherein the agent is an anthracycline, wherein the anthracycline is mitoxantrone or an analogue or derivative thereof.

7628. The method of claim 7605 wherein the agent is a platinum compound.

7629. The method of claim 7605 wherein the agent is a nitrosourea.

7630. The method of claim 7605 wherein the agent is a nitroimidazole.

7631. The method of claim 7605 wherein the agent is a folic acid antagonist.

7632. The method of claim 7605 wherein the agent is a cytidine analogue.

7633. The method of claim 7605 wherein the agent is a pyrimidine analogue.

7634. The method of claim 7605 wherein the agent is a fluoropyrimidine analogue.

7635. The method of claim 7605 wherein the agent is a purine analogue.

7636. The method of claim 7605 wherein the agent is a nitrogen mustard or an analogue or derivative thereof.

7813. The method of claim 7605, wherein the device comprises a second pharmaceutically active agent.

7815. The method of claim 7605 wherein the device comprises an agent that inhibits infection.

7612-7613. -7613. (canceled)

7637-7812. -7812. (canceled)

7814. (canceled)

7816-11180. -11180. (canceled)